- Home
- / Trinity Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Trinity Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2
2024-10-29
Market Capitalization
$19.1 M
2024-10-29
Revenue
$61.6 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 97.0M | 90.4M | 102.0M | 93.0M | 74.8M | 59.6M | 61.6M |
| Cost of goods sold | 51.5M | 47.4M | 53.4M | 52.1M | 50.4M | 35.6M | 38.2M |
| Gross profit | 45.7M | 43.1M | 50.4M | 45.5M | 24.7M | 24.2M | 23.3M |
| Gross profit margin, % | 47.7% | 49.5% | 48.9% | 33.1% | 40.5% | 37.9% | |
| Operating expense total | 34.4M | 38.2M | 32.6M | 30.0M | 33.4M | 37.9M | 40.8M |
| Depreciation and amortization | 29.5M | 27.8M | 9.1M | 7.7M | 11.4M | 1.9M | |
| EBITDA | 11.3M | 4.9M | 17.9M | 15.5M | (8.7M) | (13.8M) | (17.5M) |
| EBITDA margin, % | 5.4% | 17.5% | 16.7% | -11.6% | -23.1% | -28.5% | |
| EBIT | (18.3M) | (22.9M) | 17.9M | 6.4M | (16.3M) | (12.5M) | (19.4M) |
| EBIT margin, % | -25.3% | 17.5% | 6.9% | -21.9% | -20.9% | -31.5% | |
| Interest income | 2.1M | 697.0K | 36.0K | 3.0K | |||
| Interest expense | 5.1M | 6.6M | 6.8M | 7.1M | 24.7M | 11.1M | 13.1M |
| Pre tax profit | (23.2M) | (29.9M) | (6.6M) | 751.0K | (41.2M) | (24.1M) | (30.7M) |
| Income tax expense | (1.1M) | (1.0M) | (620.0K) | (178.0K) | (192.0K) | (59.0K) | 486.0K |
| Net Income | (22.1M) | (28.9M) | (6.0M) | 929.0K | (41.0M) | (24.0M) | (31.2M) |